Bioanalytical
Options in Advanced Therapeutic Monoclonal Antibody Analysis
Sep 18 2012
Author: by Ken Cook on behalf of Thermo Scientific
Protein Biopharmaceuticals–Challenges in Characterisation
Monoclonal antibody (mAb) biopharmaceuticals form the largest part of a growing biotherapeutics drug market and produced a requirement to develop new analytical characterisation methods. These large biomolecules are very different from the world of small molecule drugs and require different types of characterisation with very different methodology. Small molecules produce a limited number of impurities compared to a mAb which theoretically can have almost 10,000 variant molecules due to the size and complexity.
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
Jan 20 2025 Amsterdam, Netherlands
Feb 03 2025 Dubai, UAE
Feb 05 2025 Guangzhou, China
Mar 01 2025 Boston, MA, USA
Mar 04 2025 Berlin, Germany
